Commentary

Podcast

Maternal Health Inequities: Improving Access to Postpartum Depression Treatment

Author(s):

Douglas Weber, MD, explains how zuranolone has changed the landscape for postpartum depression treatment, addressing a gap in care within maternal health.

Zuranolone (Zurzuvae; Sage Therapeutics/Biogen), the first oral medication approved by the FDA for postpartum depression (PPD), became available at the end of last year, offering physicians and patients an effective and more convenient treatment option for managing PPD.

In this episode of Managed Care Cast, hosted by the Center on Health Equity & Access, Douglas Weber, MD, OB-GYN at MomDoc, explained why this therapy has impacted maternal and postpartum care. Previously, treatment for PPD was limited to intravenous (IV) administration of brexanolone (Zulresso) or commonly prescribed antidepressant medications which are not necessarily designed to address the hormonal components of PPD.

iTunes
TuneIn
Stitcher
Spotify

Related Videos
Kimberly Westrich, MA, chief strategy officer, NPC
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
Erin Weber, MS
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Erin Weber, MS
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo